DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
23 10 2023
Historique:
received: 04 10 2022
accepted: 11 10 2023
medline: 27 10 2023
pubmed: 24 10 2023
entrez: 23 10 2023
Statut: epublish

Résumé

Immunotherapies targeting cancer-specific neoantigens have revolutionized the treatment of cancer patients. Recent evidence suggests that epigenetic therapies synergize with immunotherapies, mediated by the de-repression of endogenous retroviral element (ERV)-encoded promoters, and the initiation of transcription. Here, we use deep RNA sequencing from cancer cell lines treated with DNA methyltransferase inhibitor (DNMTi) and/or Histone deacetylase inhibitor (HDACi), to assemble a de novo transcriptome and identify several thousand ERV-derived, treatment-induced novel polyadenylated transcripts (TINPATs). Using immunopeptidomics, we demonstrate the human leukocyte antigen (HLA) presentation of 45 spectra-validated treatment-induced neopeptides (t-neopeptides) arising from TINPATs. We illustrate the potential of the identified t-neopeptides to elicit a T-cell response to effectively target cancer cells. We further verify the presence of t-neopeptides in AML patient samples after in vivo treatment with the DNMT inhibitor Decitabine. Our findings highlight the potential of ERV-derived neoantigens in epigenetic and immune therapies.

Identifiants

pubmed: 37872136
doi: 10.1038/s41467-023-42417-w
pii: 10.1038/s41467-023-42417-w
pmc: PMC10593957
doi:

Substances chimiques

Histone Deacetylase Inhibitors 0
Histocompatibility Antigens Class I 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6731

Informations de copyright

© 2023. Springer Nature Limited.

Références

Cell Mol Life Sci. 2022 Mar 3;79(3):171
pubmed: 35239002
Leukemia. 2021 Jul;35(7):1873-1889
pubmed: 33958699
Cancer Immunol Immunother. 2013 Sep;62(9):1485-97
pubmed: 23817722
Breast Cancer Res Treat. 2016 Apr;156(2):237-47
pubmed: 26960711
Nucleic Acids Res. 2019 Jan 8;47(D1):D766-D773
pubmed: 30357393
Nature. 2021 Jul;595(7866):309-314
pubmed: 33953401
Cell Mol Immunol. 2019 Apr;16(4):401-409
pubmed: 29622799
N Engl J Med. 2020 Aug 13;383(7):650-663
pubmed: 32786190
Oncoimmunology. 2015 Jul 01;5(5):e1065369
pubmed: 27467910
Adv Ther. 2022 Apr;39(4):1474-1488
pubmed: 34786648
Genome Med. 2019 Dec 23;11(1):86
pubmed: 31870430
Mol Cell Proteomics. 2007 Jan;6(1):102-13
pubmed: 17074750
Exp Hematol Oncol. 2020 Sep 03;9:22
pubmed: 32908796
Int J Mol Sci. 2019 Mar 20;20(6):
pubmed: 30897713
PLoS Comput Biol. 2013;9(8):e1003118
pubmed: 23950696
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nat Commun. 2019 Nov 19;10(1):5228
pubmed: 31745090
Methods Mol Biol. 2007;409:75-93
pubmed: 18449993
Blood. 2019 Feb 7;133(6):550-565
pubmed: 30530751
Cancer Cell. 2012 Mar 20;21(3):430-46
pubmed: 22439938
J Exp Med. 2008 Mar 17;205(3):595-610
pubmed: 18299400
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Oncoimmunology. 2018 Feb 14;7(4):e1316438
pubmed: 29632711
J Am Soc Mass Spectrom. 1994 Nov;5(11):976-89
pubmed: 24226387
Cancer Res. 2016 Apr 1;76(7):1683-9
pubmed: 26988985
Theory Biosci. 2012 Dec;131(4):281-5
pubmed: 22872506
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Nature. 2014 Nov 27;515(7528):572-6
pubmed: 25428506
Genome Biol. 2014;15(12):550
pubmed: 25516281
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Nat Commun. 2020 Nov 9;11(1):5660
pubmed: 33168830
Methods Mol Biol. 2019;1988:123-136
pubmed: 31147937
Nat Biotechnol. 2020 Mar;38(3):276-278
pubmed: 32055031
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Immunology. 2018 Jul;154(3):331-345
pubmed: 29658117
Leuk Res. 2018 Sep;72:20-26
pubmed: 30064039
Bioinformatics. 2016 Feb 15;32(4):587-9
pubmed: 26508757
Genome Res. 2014 Apr;24(4):708-17
pubmed: 24676093
Methods. 2017 Aug 15;126:112-129
pubmed: 28579404
Front Immunol. 2021 Jul 08;12:705974
pubmed: 34305947
Nucleic Acids Res. 2020 Jul 2;48(W1):W449-W454
pubmed: 32406916
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Leukemia. 2015 Mar;29(3):647-59
pubmed: 25092142
Blood Adv. 2020 Sep 22;4(18):4430-4437
pubmed: 32936907
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75
pubmed: 25548167
Oncotarget. 2014 Feb 15;5(3):587-98
pubmed: 24583822
Nucleic Acids Res. 2018 Jan 4;46(D1):D794-D801
pubmed: 29126249
Nat Methods. 2007 Nov;4(11):923-5
pubmed: 17952086
Nat Biotechnol. 2015 Mar;33(3):290-5
pubmed: 25690850
J Immunol. 2011 Jul 1;187(1):7-9
pubmed: 21690331
Cell Rep. 2022 Jun 7;39(10):110916
pubmed: 35675780
J Hepatol. 2016 Oct;65(4):849-855
pubmed: 27397612
Blood Cancer J. 2016 Apr 08;6:e411
pubmed: 27058226
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Nat Genet. 2017 Jul;49(7):1052-1060
pubmed: 28604729
Nature. 2019 Jan;565(7738):240-245
pubmed: 30568303
Bioinformatics. 2019 Sep 1;35(17):3151-3153
pubmed: 30689724
Bone Marrow Transplant. 2019 Nov;54(11):1815-1826
pubmed: 31089280
Cancer Res. 2020 Jun 15;80(12):2441-2450
pubmed: 32245794
Mol Cell. 2022 Jul 7;82(13):2458-2471.e9
pubmed: 35550257
Cancer Res. 2008 Jan 1;68(1):44-54
pubmed: 18172295
Nat Biotechnol. 2022 Feb;40(2):209-217
pubmed: 34663921
J Clin Oncol. 2013 Nov 10;31(32):e439-42
pubmed: 24043743
Cancer Discov. 2011 Dec;1(7):598-607
pubmed: 22586682
F1000Res. 2020 Apr 28;9:304
pubmed: 32489650
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):498-504
pubmed: 15701833
Nature. 2021 Mar;591(7850):E20
pubmed: 33654322
Nucleic Acids Res. 2009 Jan;37(Database issue):D816-9
pubmed: 18838390
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W187-91
pubmed: 24799436
Mol Cell Proteomics. 2014 Aug;13(8):2056-71
pubmed: 24623587
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Nat Commun. 2016 Nov 21;7:13404
pubmed: 27869121
Semin Cancer Biol. 2018 Aug;51:68-79
pubmed: 29129488
Nucleic Acids Res. 2020 Jan 8;48(D1):D941-D947
pubmed: 31584097
Genome Res. 2019 Oct;29(10):1578-1590
pubmed: 31537638
Int J Cancer. 2012 Jul 1;131(1):140-9
pubmed: 21858810
Blood Adv. 2018 Feb 13;2(3):224-234
pubmed: 29386195
Methods Mol Biol. 2016;1418:335-51
pubmed: 27008022
Blood Cancer J. 2020 Feb 28;10(2):24
pubmed: 32111817
Mol Cell Proteomics. 2014 Mar;13(3):792-810
pubmed: 24396086
Cell. 2015 Aug 27;162(5):974-86
pubmed: 26317466
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Clin Epigenetics. 2017 May 30;9:59
pubmed: 28572863
Nat Commun. 2020 Mar 10;11(1):1293
pubmed: 32157095

Auteurs

Ashish Goyal (A)

Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Jens Bauer (J)

Department of Peptide-based Immunotherapy, University of Tübingen and University Hospital Tübingen, Tübingen, Germany.
Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.

Joschka Hey (J)

Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
German-Israeli Helmholtz Research School in Cancer Biology, Heidelberg, Germany.
German Center for Lung Research, (DZL) partner site Heidelberg, Heidelberg, Germany.

Dimitris N Papageorgiou (DN)

Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heidelberg University, Medical Faculty, Heidelberg, Germany.

Ekaterina Stepanova (E)

Translational Control and Metabolism, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Michael Daskalakis (M)

Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Hematology and Central Hematology Laboratory, Inselspital, Bern, University Hospital, University of Bern, Bern, Switzerland.

Jonas Scheid (J)

Department of Peptide-based Immunotherapy, University of Tübingen and University Hospital Tübingen, Tübingen, Germany.
Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
Quantitative Biology Center (QBiC), University of Tübingen, Tübingen, Germany.

Marissa Dubbelaar (M)

Department of Peptide-based Immunotherapy, University of Tübingen and University Hospital Tübingen, Tübingen, Germany.
Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
Quantitative Biology Center (QBiC), University of Tübingen, Tübingen, Germany.

Boris Klimovich (B)

Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.

Dominic Schwarz (D)

Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Melanie Märklin (M)

Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.

Malte Roerden (M)

Department of Peptide-based Immunotherapy, University of Tübingen and University Hospital Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.

Yu-Yu Lin (YY)

Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Tobias Ma (T)

Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Oliver Mücke (O)

Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Hans-Georg Rammensee (HG)

Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.

Michael Lübbert (M)

Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Fabricio Loayza-Puch (F)

Translational Control and Metabolism, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Jeroen Krijgsveld (J)

Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heidelberg University, Medical Faculty, Heidelberg, Germany.

Juliane S Walz (JS)

Department of Peptide-based Immunotherapy, University of Tübingen and University Hospital Tübingen, Tübingen, Germany. juliane.walz@med.uni-tuebingen.de.
Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany. juliane.walz@med.uni-tuebingen.de.
Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany. juliane.walz@med.uni-tuebingen.de.
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany. juliane.walz@med.uni-tuebingen.de.

Christoph Plass (C)

Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany. c.plass@dkfz.de.
German Center for Lung Research, (DZL) partner site Heidelberg, Heidelberg, Germany. c.plass@dkfz.de.
German Cancer Consortium (DKTK), Heidelberg, Germany. c.plass@dkfz.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH